Allelic variation of human serotonin transporter gene expression.

PubWeight™: 7.08‹?› | Rank: Top 1%

🔗 View Article (PMID 8632190)

Published in J Neurochem on June 01, 1996

Authors

A Heils1, A Teufel, S Petri, G Stöber, P Riederer, D Bengel, K P Lesch

Author Affiliations

1: Department of Psychiatry, University of Würzburg, Germany.

Articles citing this

(truncated to the top 100)

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27

Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry (2007) 4.71

Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65

Candidate gene studies of ADHD: a meta-analytic review. Hum Genet (2009) 3.56

HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry (2007) 2.87

Medication treatment of different types of alcoholism. Am J Psychiatry (2010) 2.69

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59

Looking on the bright side: biased attention and the human serotonin transporter gene. Proc Biol Sci (2009) 2.49

The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet (2008) 2.44

Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study. Am J Psychiatry (2007) 2.37

Serotonergic function, two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression. Psychol Bull (2008) 2.24

Association between promoter methylation of serotonin transporter gene and depressive symptoms: a monozygotic twin study. Psychosom Med (2013) 2.19

The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18

Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry (2008) 2.01

Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry (2009) 1.97

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80

Association of the serotonin transporter gene promoter region (5-HTTLPR) polymorphism with biased attention for emotional stimuli. J Abnorm Psychol (2009) 1.74

The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65

Social disadvantage, genetic sensitivity, and children's telomere length. Proc Natl Acad Sci U S A (2014) 1.64

A genetically mediated bias in decision making driven by failure of amygdala control. J Neurosci (2009) 1.59

Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol (2013) 1.57

How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56

Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut (2004) 1.55

S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci (2013) 1.52

Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51

Plasma serotonin levels and the platelet serotonin transporter. J Neurochem (2007) 1.49

5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet (2009) 1.49

Trends in ambulatory self-report: the role of momentary experience in psychosomatic medicine. Psychosom Med (2012) 1.47

AVPR1a and SLC6A4 gene polymorphisms are associated with creative dance performance. PLoS Genet (2005) 1.45

Association of functional polymorphisms from brain-derived neurotrophic factor and serotonin-related genes with depressive symptoms after a medical stressor in older adults. PLoS One (2015) 1.42

Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry (2007) 1.40

The human serotonin transporter gene polymorphism--basic research and clinical implications. J Neural Transm (Vienna) (1997) 1.39

Influence of Serotonin Transporter Gene Polymorphisms and Adverse Life Events on Depressive Symptoms in the Elderly: A Population-Based Study. PLoS One (2015) 1.38

Accurate, Large-Scale Genotyping of 5HTTLPR and Flanking Single Nucleotide Polymorphisms in an Association Study of Depression, Anxiety, and Personality Measures. Biol Psychiatry (2009) 1.37

Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One (2010) 1.36

Central effects of estradiol in the regulation of food intake, body weight, and adiposity. J Steroid Biochem Mol Biol (2009) 1.33

The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci (2007) 1.32

Epigenetic regulation of serotonin transporter expression and behavior in infant rhesus macaques. Genes Brain Behav (2010) 1.29

Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28

Connectomic intermediate phenotypes for psychiatric disorders. Front Psychiatry (2012) 1.26

A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol (2011) 1.25

Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. Brain Behav Immun (2007) 1.23

Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv (2010) 1.23

Life stress, 5-HTTLPR and mental disorder: findings from a 30-year longitudinal study. Br J Psychiatry (2011) 1.22

The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety (2010) 1.22

Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci (2010) 1.22

Combinatorial interaction between two human serotonin transporter gene variable number tandem repeats and their regulation by CTCF. J Neurochem (2009) 1.20

Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. PLoS One (2012) 1.20

Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry (2008) 1.18

Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.15

Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder. Mol Psychiatry (2002) 1.15

Genetics of migraine in the age of genome-wide association studies. J Headache Pain (2011) 1.15

Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with premature ejaculation in a Turkish population. Asian J Androl (2009) 1.13

Interactions between serotonin transporter gene haplotypes and quality of mothers' parenting predict the development of children's noncompliance. Dev Psychol (2011) 1.12

Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory. Proc Natl Acad Sci U S A (2012) 1.12

Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion. Neuropsychopharmacology (2006) 1.12

5-HTTLPR moderates the effect of relational peer victimization on depressive symptoms in adolescent girls. J Child Psychol Psychiatry (2009) 1.12

Confluence of genes, environment, development, and behavior in a post Genome-Wide Association Study world. Dev Psychopathol (2012) 1.10

Genetic determinants of time perception mediated by the serotonergic system. PLoS One (2010) 1.10

Serotonin transporter polymorphism predicts waking cortisol in young girls. Psychoneuroendocrinology (2009) 1.09

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) (2003) 1.09

Role of variation in the serotonin transporter protein gene (SLC6A4) in trait disturbances in the ventral anterior cingulate in bipolar disorder. Neuropsychopharmacology (2008) 1.08

Is there an optimum endurance polygenic profile? J Physiol (2009) 1.08

The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol (2009) 1.08

Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry (2010) 1.07

Genetics of anxiety and trauma-related disorders. Neuroscience (2009) 1.07

Stress, genes and the biology of suicidal behavior. Psychiatr Clin North Am (2008) 1.07

Genetic sensitivity to the caregiving context: the influence of 5httlpr and BDNF val66met on indiscriminate social behavior. Physiol Behav (2011) 1.07

Genes, Economics, and Happiness. J Neurosci Psychol Econ (2012) 1.07

Depression research: where are we now? Mol Brain (2010) 1.06

Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters. Neuropsychiatr Dis Treat (2010) 1.06

5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. Psychiatr Genet (2011) 1.05

Dopaminergic, serotonergic, and oxytonergic candidate genes associated with infant attachment security and disorganization? In search of main and interaction effects. J Child Psychol Psychiatry (2011) 1.05

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med (2012) 1.04

Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population. Eur Arch Psychiatry Clin Neurosci (2008) 1.04

rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgrad Med (2014) 1.04

An imaging genetics approach to understanding social influence. Front Hum Neurosci (2012) 1.04

The possible influence of impulsivity and dietary restraint on associations between serotonin genes and binge eating. J Psychiatr Res (2009) 1.04

Brief report: aggression and stereotypic behavior in males with fragile X syndrome--moderating secondary genes in a "single gene" disorder. J Autism Dev Disord (2007) 1.03

Serotonin transporter gene promoter region polymorphism and selective processing of emotional images. Biol Psychol (2009) 1.03

The BDNF Val66Met polymorphism is associated with rumination in healthy adults. Emotion (2009) 1.03

Brain serotonin receptors and transporters: initiation vs. termination of escalated aggression. Psychopharmacology (Berl) (2010) 1.03

Interaction between the dopamine D4 receptor and the serotonin transporter promoter polymorphisms in alcohol and tobacco use among 15-year-olds. Neurogenetics (2006) 1.02

Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis (2010) 1.02

Serotonin transporters: implications for antidepressant drug development. AAPS J (2005) 1.02

Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatol Int (2010) 1.02

Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology (Berl) (2004) 1.01

Serotonin transporter gene-linked polymorphic region (5-HTTLPR) influences decision making under ambiguity and risk in a large Chinese sample. Neuropharmacology (2010) 1.01

5-HTTLPR and BDNF Val66Met polymorphisms moderate effects of stress on rumination. Genes Brain Behav (2011) 1.01

Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. Biol Psychiatry (2009) 1.00

Altered timing of amygdala activation during sad mood elaboration as a function of 5-HTTLPR. Soc Cogn Affect Neurosci (2010) 1.00

The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am (2009) 1.00

Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Dis (2012) 1.00

Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clin Exp Res (2009) 0.99

Fetal effects of psychoactive drugs. Clin Perinatol (2009) 0.99

Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin Exp Res (2008) 0.98

Polymorphisms of the Serotonin Transporter Gene and G-Protein β3 Subunit Gene in Korean Children with Irritable Bowel Syndrome and Functional Dyspepsia. Gut Liver (2012) 0.98

Neural and behavioral responses to threatening emotion faces in children as a function of the short allele of the serotonin transporter gene. Biol Psychol (2010) 0.98

The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol (2014) 0.98

Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolesc Psychiatry (2010) 0.97

Articles by these authors

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04

Pharmacogenetic prediction of clozapine response. Lancet (2000) 3.10

Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol (1998) 2.94

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91

Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry (2002) 2.85

Serotonin transporter gene polymorphism, differential early rearing, and behavior in rhesus monkey neonates. Mol Psychiatry (2002) 2.65

A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60

Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol (1994) 2.43

Safety of self-injection of gold and methotrexate. J Rheumatol (1999) 2.39

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27

A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatry (2001) 2.27

Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 2.22

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19

Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 2.19

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17

Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet (1999) 2.16

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10

CNTF and endogenous psychoses? Nat Genet (1996) 2.02

Exclusion of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene as a candidate for catatonic schizophrenia in a large family supporting the chromosome 15q13-22 locus. Mol Psychiatry (2002) 2.01

Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98

Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97

Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry (1997) 1.94

The utility of the non-human primate; model for studying gene by environment interactions in behavioral research. Genes Brain Behav (2003) 1.91

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90

Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89

Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86

Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81

Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest (2000) 1.80

Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70

Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun (1998) 1.69

The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64

The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62

Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55

Exploring the genetic link between RLS and ADHD. J Psychiatr Res (2009) 1.55

Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54

Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53

Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer (2006) 1.48

Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci (2000) 1.46

Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44

N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40

How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol (1995) 1.40

The human serotonin transporter gene polymorphism--basic research and clinical implications. J Neural Transm (Vienna) (1997) 1.39

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38

Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38

Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37

Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37

Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36

Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35

Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci (2001) 1.34

Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33

Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33

Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J Neurosci (2001) 1.33

Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci (2000) 1.29

Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28

Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26

Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26

Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm (1976) 1.26

Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 1.26

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol (1991) 1.26

Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res (1999) 1.24

Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23

Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem (1997) 1.21

Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet (1997) 1.21

Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther (1999) 1.20

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20

Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm (Vienna) (2005) 1.19

Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol (2012) 1.18

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm (Vienna) (2003) 1.18

Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. Mol Psychiatry (2008) 1.18

Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet (2000) 1.17

Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Arch Gen Psychiatry (1998) 1.16

The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15

Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med (1980) 1.15

Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. Psychiatry Res (1999) 1.13

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13

Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl (1994) 1.11

Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10

Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol (2000) 1.10

Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol (2001) 1.10

Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. Cereb Cortex (2006) 1.10

Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett (2000) 1.10